Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, discusses CMS' proposal to treat biosimilars as generics for the purpose of cost-sharing.
CMS has proposed treating biosimilars like generics for the purpose of cost-sharing under Medicare Part D. What is your organization’s position on this proposed change?
Right now, the Global Healthy Living Foundation is still formulating our official position on this issue. However, we are huge proponents of biosimilars and we have been for quite some time. Biosimilars are not generics, and we believe that their true success or failure will be measured on biosimilars living up to their promise of safety and their promise to deliver savings directly to the patient—in the form of lower premiums, lower copay or coinsurance, and deductibles. As we consider CMS’s proposal, we keep patient impact at the center of all of those considerations.